Pernilla Videhult Pierre

Pernilla Videhult Pierre

Adjunkt
Telefon: +46852483867
Besöksadress: Enheten för audiologi, Alfred Nobels Allé 10, plan 5, 14152 Huddinge
Postadress: H9 Klinisk vetenskap, intervention och teknik, H9 CLINTEC Audiologi, 171 77 Stockholm
Del av:

Om mig

  • Medicine doktor, apotekare, adjunkt och forskare
    *Samarbeten utanför Enheten för audiologi*
    Filip Asp, med dr, civilingenjör, Karolinska universitetssjukhuset,
    Stockholm
    Cecilia Engmér Berglin, medicine doktor, specialistläkare i
    öron-näsa-hals, Karolinska universitetssjukhuset, Stockholm.
    Anders Fridberger, professor i neurovetenskap, Institutionen för klinisk och
    experimentell medicin, Cellbiologi, Linköpings universitet, Linköping.
    Christina Forshell Hederstierna, medicine doktor, överläkare i audiologi,
    Karolinska universitetssjukhuset, Stockholm.
    Mikael Hedeland, professor i analytisk farmaceutisk kemi, Uppsala
    universitet, Uppsala .
    Göran Laurell, professor i öron-näs-halssjukdomar, Uppsala universitet,
    överläkare, Akademiska sjukhuset, Uppsala.
    Curt Pettersson, professor emeritus i analytisk farmaceutisk kemi, Uppsala
    universitet, Uppsala.
    Ulf Rosenhall, professor emeritus i klinisk audiologi, överläkare,
    Karolinska universitetssjukhuset, Stockholm.
    Henrik Smeds, med dr, överläkare i öron-näsa-hals, Karolinska
    universitetssjukhuset.
    *Publikationer*
    /*Vetenskapliga originalartiklar*/
    1. *Videhult Pierre P*, Fransson A, Kisiel A. M., Laurell G. Hydrogen Gas
    Inhalation Attenuates Acute Impulse Noise Trauma: A Preclinical In Vivo
    Study. Accepterad av Ann Otol Rhinol Laryngol 2022.
    2. Fransson A, *Videhult Pierre P*, Risling M, Laurell G. Inhalation of
    molecular hydrogen, a rescue treatment for noise-induced hearing loss. Front
    Cell Neurosci 2021. DOI: 10.3389/fncel.2021.658662
    3. *Videhult Pierre P*, Rasmussen JE, Nikkhou Aski S, Damberg P, Laurell G.
    High-dose furosemide enhances the magnetic resonance signal of systemic
    gadolinium in the mammalian cochlea. Otol Neurotol 2020.
    https://doi.org/10.1097/MAO.0000000000002571
    4. *Videhult Pierre P*, Eklöf M, Smeds H, Asp F. Cochlear implantation with
    the CI512 and CI532 pre-curved electrode arrays: one year speech recognition
    and intraoperative thresholds of electrically evoked compound action
    potentials. Audiol Neurotol 2019
  • 24: 299-308. DOI: 10.1159/000504592
    5. Pirttilä K, *Videhult Pierre P*, Haglöf J, Engskog M, Hedeland M,
    Laurell G, Arvidsson T, Pettersson C. An LCMS-based untargeted metabolomics
    protocol for cochlear perilymph: highlighting metabolic effects of hydrogen
    gas on the inner ear of noise exposed Guinea pigs.
    Metabolomics 2019
  • 15(10):138. DOI: 10.1007/s11306-019-1595-1
    6. *Videhult Pierre P*, Fransson A, Kisiel MA, Damberg P, Nikkhou Aski S,
    Andersson M, et al. Middle Ear Administration of a Particulate Chitosan Gel
    in an in vivo Model of Cisplatin Ototoxicity. Front Cell
    Neurosci 2019
  • 13:268. DOI: 10.3389/fncel.2019.00268
    7. Fransson AE, Kisiel M, Pirttilä K, Pettersson C, *Videhult Pierre P*,
    Laurell GFE. Hydrogen inhalation protects against ototoxicity induced by
    intravenous cisplatin in the guinea pig. Front Cell Neurosci 2017 Sep
    13
  • 11:280. DOI: 10.3389/fncel.2017.00280.
    8. *Videhult Pierre P*, Haglöf J, Linder B, Engskog MKR, Arvidsson T,
    Pettersson C, Fransson A, Laurell G. Cisplatin-induced metabolome changes in
    serum: an experimental approach to identify markers for ototoxicity. Acta
    Otolaryngol 2017 Oct
  • 137(10):1024-1030. DOI: 10.1080/00016489.2017.1325006.
    9. Engmér Berglin C, *Videhult Pierre P*, Ekborn A, Bramer T, Edsman K,
    Hultcrantz M, Laurell G. Local treatment of the inner ear: a study of three
    different polymers aimed for middle ear administration. Acta
    Otolaryngol 2015
  • 135(10):985-94. DOI: 10.3109/00016489.2015.1058534.
    10. *Videhult Pierre P*, Johnson AC, Fridberger A. Subjective and clinically
    assessed hearing loss
  • a cross-sectional register-based study on a Swedish
    population aged 18 through 50 years. PLoS One 2015 Apr 13
  • 10(4):e0123290.
    DOI: 10.1371/journal.pone.0123290.
    11. *Pierre PV*, Fridberger A, Wikman A, Alexanderson K. Self-reported
    hearing difficulties, main income sources, and socio-economic status
  • a
    cross-sectional population-based study in Sweden. BMC Public Health 2012 Oct
    15
  • 12:874. DOI: 10.1186/1471-2458-12-874.
    12. Berglin CE, *Pierre PV*, Bramer T, Edsman K, Ehrsson H, Eksborg S,
    Laurell G. Prevention of cisplatin-induced hearing loss by administration of
    a thiosulfate-containing gel to the middle ear in a guinea pig model. Cancer
    Chemother Pharmacol 2011 Dec
  • 68(6):1547-56. DOI: 10.1007/s00280-011-1656-2.
    13. *Pierre PV*, Wallin I, Eksborg S, Ehrsson H. Quantitative liquid
    chromatographic determination of intact cisplatin in blood with
    microwave-assisted post-column derivatization and UV detection. J Pharm
    Biomed Anal 2011 Aug 25
  • 56(1):126-30. DOI: 10.1016/j.jpba.2011.04.028.
    14. *Pierre PV*, Engmér C, Wallin I, Laurell G, Ehrsson H. High
    concentrations of thiosulfate in scala tympani perilymph after systemic
    administration in the guinea pig. Acta Otolaryngol 2009 Feb
  • 129(2):132-7.
    DOI: 10.1080/00016480802116232.
    15. *Videhult P*, Laurell G, Wallin I, Ehrsson H. Kinetics of Cisplatin and
    its monohydrated complex with sulfur-containing compounds designed for local
    otoprotective administration. Exp Biol Med (Maywood) 2006
    Nov
  • 231(10):1638-45. DOI: 10.1177/153537020623101009
    16. *Videhult P*, Yachnin J, Jerremalm E, Lewensohn R, Ehrsson H. Synthesis
    and cytotoxicity of the dihydrated complex of oxaliplatin. Cancer Lett 2002
    Jun 28
  • 180(2):191-4. DOI: 10.1016/s0304- 3835(02)00002-2
    17. Jerremalm E, *Videhult P*, Alvelius G, Griffiths WJ, Bergman T, Eksborg
    S, Ehrsson H. Alkaline hydrolysis of oxaliplatin--isolation and
    identification of the oxalato monodentate intermediate. J Pharm Sci 2002
    Oct
  • 91(10):2116-21. DOI: 10.1002/jps.10201
    */Vetenskapliga översiktsartiklar/*
    Cortés Fuentes IA, *Videhult Pierre P*, Engmér Berglin C. Improving
    clinical outcomes in cochlear implantation using glucocorticoid therapy: a
    review. Ear Hear 2019, Apr 30. doi: 10.1097/AUD.0000000000000740.
    /*Bokkapitel*/
    Laurell G, *Videhult Pierre P*. Hearing loss after cisplatin: oxidative
    stress pathways and potential for protection. I: Armstrong D, redaktör. Free
    Radicals in ENT Pathology. New York: Springer
  • 2015. s. 217-241.
    /*Avhandling*/
    *Videhult Pierre P*. Doktorsavhandling: Cisplatin, a platinum-containing
    antineoplastic drug: perspectives on analytical chemistry and prevention of
    ototoxicity. Karolinska Institutet 2010, Stockholm.

Artiklar

Alla övriga publikationer

Anställningar

  • Adjunkt, Klinisk vetenskap, intervention och teknik, Karolinska Institutet, 2019-

Examina och utbildning

  • Medicine Doktorsexamen, Institutionen för onkologi-patologi, Karolinska Institutet, 2010

Nyheter från KI

Kalenderhändelser från KI